$AGMB

AgomAb Therapeutics NV

AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibro-inflammatory diseases. Headquartered in Antwerp, Belgium, it also has chemistry laboratory facilities in Touro, Spain, and an office in Cambridge, Massachusetts. Its pipeline includes small-molecule and antibody candidates, with a focus on chronic fibrotic disorders. Ontunisertib is an oral, gastrointestinal-restricted ALK5 inhibitor in development for fibrostenosing Crohn’s disease, while inhaled ALK5 inhibitor AGMB-447 is being developed for idiopathic pulmonary fibrosis. The discovery and preclinical portfolio includes AGMB-101, an HGF-mimetic monoclonal antibody that stimulates the MET receptor. AgomAb conducts research and development and retains exclusive, worldwide development and commercialization rights to its product candidates and preclinical programs. Its work also includes early-stage discovery programs. The company acquired its lead programs through its acquisition of Origo Biopharma, a Spanish clinical-stage biotechnology company.

No enriched coverage for $AGMB in the last 7 days.

$281K
—
Epstein David R
0%
See all $AGMB insider activity →
Low

Epstein David R purchased $89K of AGMB

Epstein David R purchased 14,980 shares of AgomAb Therapeutics NV (AGMB) at an average of $5.92 ($5.75–$6.02) across 4 trades on 2026-11-13.

Epstein David R purchased $104K of AGMB

Epstein David R purchased 15,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $6.90 ($6.81–$6.98, $0.10M total) across 3 trades on 2026-11-05.

Epstein David R purchased $89K of AGMB

Epstein David R purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.88 ($8.86–$8.90) across 2 trades on 2026-10-21.

AGMB sentiment & insider activity

Recent AGMB coverage spans insider activity and financial news.

In the last 30 days, AGMB insiders filed 9 SEC Form 4 transactions — 9 purchases ($281K) and no sales. The most active reporter was Epstein David R with 9 filings.

What's driving AGMB

AlphAI scores every news story that mentions AGMB with an AI model for sentiment and relevance, and aggregates insider trades from AgomAb Therapeutics NV's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AGMB

Score

Agomab Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $35 price target for Agomab Therapeutics (AGMB) after a panel discussion at United European Gastroenterology Week. The stock trades at $8.73, with potential upside of over 300%. Analysts highlight the company's financial strength and the potential of its drug ontunisertib for fibrostenosing Crohn’s disease. Other analysts have also initiated coverage with positive ratings and price targets.

$AGMBMedAI 8/10

Agomab Doses First Patient in Global Phase 2b NOV-ERA Trial for Fibrostenosing Crohn’s Disease

Agomab Therapeutics (AGMB) dosed the first patient in its global Phase 2b NOV-ERA trial for fibrostenosing Crohn’s disease. The study will enroll 320 adults to evaluate ontunisertib over 52 weeks, with a primary endpoint at Week 24. The trial follows positive Phase 2a data and triggers a €7 million milestone payment. AGMB has a Buy rating and $28 price target from analysts.

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

Agomab Therapeutics will present Phase 2a STENOVA trial data on ontunisertib for Fibrostenosing Crohn’s disease at UEG Week 2026. The open-label extension results support the initiation of the global NOV-ERA Phase 2b study. Agomab will also host a symposium on fibro-inflammation in IBD. Ontunisertib is an investigational drug designed to inhibit ALK5/TGF-β in the GI tract.

Related tickers